Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach

详细信息    查看全文

• 作者：Masahiro Takada (1)
  Hiroshi Terunuma (2) (3)
  Xuewen Deng (2)
  Md. Zahidunnabi Dewan (4)
  Shigehira Saji (5)
  Katsumasa Kuroi (5)
  Naoki Yamamoto (6) (7)
  Masakazu Toi (1)
  
• 关键词：Breast cancer ; Metastasis ; Natural killer cell ; Chemotherapy ; Trastuzumab
• 刊名：Breast Cancer
• 出版年：2011
• 出版时间：January 2011
• 年：2011
• 卷：18
• 期：1
• 页码：64-67
• 全文大小：208KB
• 参考文献：1. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000;18:3230鈥?.
  2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783鈥?2. CrossRef
  3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659鈥?2. CrossRef
  4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673鈥?4. CrossRef
  5. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443鈥?. CrossRef
  6. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10:5650鈥?. CrossRef
  7. Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res. 2007;13:1875鈥?2. CrossRef
  8. Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997;6:655鈥?1. CrossRef
  9. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 2008;27:93鈥?10. CrossRef
  10. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat. 2007;104:267鈥?5. CrossRef
  11. Hayashi T, Imai K, Morishita Y, Hayashi I, Kusunoki Y, Nakachi K. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 2006;66:563鈥?0. CrossRef
  12. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, et al. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 2009;63:703鈥?. CrossRef
  13. Koehl U, S枚rensen J, Esser R, Zimmermann S, Gr眉ttner HP, Tonn T, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33:261鈥?. CrossRef
  14. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274鈥?1. CrossRef
  15. Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer. 2004;90:2338鈥?3.
  16. Sawada N, Ishikawa T, Fukuse Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013鈥?.
  17. Toi M, Rahman MA, Bando H, Chow LWC. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005;6:128鈥?6. CrossRef
  18. Kubo M, Morisaki T, Matsumoto K, Tasaki A, Yamanaka N, Nakashima H, et al. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunol Immunother. 2005;54:468鈥?6. CrossRef
  19. Carson WE 3rd, Shapiro CL, Crespin TR, Thornton LM, Andersen BL. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res. 2004;10:3401鈥?. CrossRef
  20. Terunuma H, Wada A, Deng X, Yasuma Y, Onishi T, Toki A, et al. Mild hyperthermia modulates the relative frequency of lymphocyte cell subpopulations: an increase in a cytolytic NK cell subset and a decrease in a regulatory T cell subset. Therm Med. 2007;23:41鈥?. CrossRef
  21. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117鈥?7. CrossRef
  22. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395鈥?02. CrossRef
  
• 作者单位：Masahiro Takada (1)
  Hiroshi Terunuma (2) (3)
  Xuewen Deng (2)
  Md. Zahidunnabi Dewan (4)
  Shigehira Saji (5)
  Katsumasa Kuroi (5)
  Naoki Yamamoto (6) (7)
  Masakazu Toi (1)
  
  1. Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
  2. Biotherapy Institute of Japan, Tokyo, Japan
  3. Tokyo Clinic Marunouchi Oazo, Tokyo, Japan
  4. Department of Pathology, New York University Medical Center, New York, USA
  5. Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
  6. Department of Molecular Virology, Tokyo Medical and Dental University, Tokyo, Japan
  7. National Institute of Infectious Diseases, Tokyo, Japan
  

文摘

A suggestive case of metastatic disease from breast cancer is reported. The HER-2-positive tumor was refractory to several agents, including anti-HER-2 therapy, trastuzumab, and lapatinib. After re-induction of trastuzumab in combination with activated natural killer (NK) cell injection therapy, tumor markers decreased, and finally a synergistic effect of taxane and capecitabine led to treatment response. This case suggests that multidisciplinary therapy including an immunological approach might be a breakthrough in the treatment of refractory disease.